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ABSTRACT 
Background: While reduction of DUP (Duration of Untreated Psychosis) is a key goal in early 
intervention strategies, the predictive value of DUP on outcome has been questioned. We 
planned this study in order to explore the impact of three different definition of “treatment 
initiation” on the predictive value of DUP on outcome in an early psychosis sample.  
Methods: 221 early psychosis patients aged 18-35 were followed-up prospectively over 36 
months. DUP was measured using three definitions for treatment onset: Initiation of 
antipsychotic medication (DUP1); engagement in a specialized programme (DUP2) and 
combination of engagement in a specialized programme and adherence to medication (DUP3).  
Results: 10% of patients never reached criteria for DUP3 and therefore were never adequately 
treated over the 36-month period of care. While DUP1 and DUP2 had a limited predictive value 
on outcome, DUP3, based on a more restrictive definition for treatment onset, was a better 
predictor of positive and negative symptoms, as well as functional outcome at 12, 24 and 36 
months. Globally, DUP3 explained 2 to 5 times more of the variance than DUP1 and DUP2, with 
effect sizes falling in the medium range according to Cohen.  
Conclusions: The limited predictive value of DUP on outcome in previous studies may be linked 
to problems of definitions that do not take adherence to treatment into account. While they need 
replication, our results suggest effort to reduce DUP should continue and aim both at early 
detection and development of engagement strategies. 
 
Key words: duration of untreated psychosis, early psychosis, first episode psychosis, treatment 
adherence 
  
INTRODUCTION 
Delay between psychosis onset and exposure to appropriate treatment or duration of 
untreated psychosis (DUP), has been identified as a key target in programs specialized in the 
treatment of the early phase of psychotic disorders, based on the rationale that it’s reduction 
should have an impact on the course of symptoms and functioning (Melle et al. , 2008). While 
numerous papers have indeed shown DUP to be significantly associated with clinical and social 
outcomes (Malla et al. , 2014, Marshall et al. , 2005), this possible correlation was modest and 
has been a matter of an intense controversy (Craig et al. , 2000, Harrigan et al. , 2003, Ho and 
Andreasen, 2001).  
Various factors may explain the contradictory nature of results in this domain and the 
only modest association found between DUP and outcomes in first episode psychosis (FEP) 
patients. First, in an extensive review, it has been suggested that considerable variability exists 
in the definition of both onset and endpoint of DUP (Compton et al. , 2007). In particular, the 
literature reveals significant differences between studies regarding the definition of treatment 
onset, hence “end” of DUP. In a previous paper, we reported that while considerable attention 
has been paid to the assessment of psychosis onset, resulting in a certain degree of consensus 
regarding its definition, this is not true for criteria applied to define the end of DUP: definitions 
applied ranged from “start of medication” to “hospitalization” and “entry to a specialized 
program”, and were therefore based on many different conceptual levels (Polari et al. , 2009). 
Second, when definition of DUP’s end is based on medication, various definitions have been 
considered, ranging from “initiation of medication”, “start of any form of treatment”, or “initiation 
of adequate treatment”, to “time of first effective treatment” (Norman and Malla, 2001, Polari, 
Berk, 2009). Thirdly, when end of DUP is based on exposure to a certain level of medication, 
the definition of “adequate treatment” can be the matter of important debate, some authors 
requiring 12 weeks of medication (Loebel et al. , 1992) while 3 weeks were sufficient for others 
(Larsen et al. , 1996). Globally, in a review of 16 FEP studies, Norman and Malla (2001) found 
that definition applied to identify initiation of treatment varied greatly. Fourthly, patients' 
adherence to the prescribed medication has not been taken into consideration in the majority of 
studies (Norman and Malla, 2001). Considering the high rate of non adherence to treatment in 
FEP patients, it is therefore likely that DUP may have been considered finished for many 
patients while they actually did not receive any adequate medication yet.  
In this context, it can be argued that such a lack of consistency in definition could be one 
of the critical factors that so far limited the conclusiveness of studies exploring consequences of 
DUP (Polari, Berk, 2009). Indeed, when applying 3 possible definitions for treatment onset in a 
FEP sample, we confirmed that estimation of DUP could vary greatly, which in turn could 
significantly influence the measurement of its impact on outcome variables. 
Considering that the existence or not of a correlation between DUP and outcome is 
critical when choosing strategies that should be applied in specialized programs for the early 
phase of psychosis, we designed the current study in order to compare different definitions of 
DUP in their ability to predict outcome in FEP patients. Our hypothesis was that when defining 
beginning of treatment in a restrictive manner on the basis of both engagement in a specialized 
program and adherence to adequate medication according to current guidelines, DUP would be 
significantly correlated to outcome. Considering some patients may never adhere to treatment 
despite our efforts (Lambert et al. , 2010) our secondary aim was to characterize patients who 
never met these restrictive criteria and could never be engaged into effective treatment within 
the 3-years of our program and therefore remained in a phase of “untreated psychosis”. 
 
MATERIAL AND METHODS 
Procedure and participants 
TIPP (Treatment and early Intervention in Psychosis Program), a specialized early 
psychosis program, was launched in 2004 at the Department of Psychiatry CHUV, in Lausanne, 
Switzerland (Baumann et al. , 2013). Entry criteria to the program are: (I) age between 18 and 
35; (II) residing in the catchment area (Lausanne and surroundings; population about 300’000); 
(III) meeting threshold criteria for psychosis, as defined by the ‘Psychosis threshold’ subscale of 
the Comprehensive Assessment of At Risk Mental States (CAARMS) scale (Yung et al. , 2005). 
Patients are referred to other treatment programs if they have psychosis related to intoxication 
or organic brain disease, or have an intelligence quotient below 70 or have been taking 
antipsychotic medication for more than a total of 6 months. This latter criteria, which allows 
admission of patients who would have been treated unsuccessfully for a limited amount of time 
explains why we refer to early psychosis rather than to first episode psychosis patients.  
The Research and Ethics Committee of the Faculty of Biology and Medicine of 
Lausanne University granted access to TIPP clinical data for research purposes. Therefore all 
patients who take part in this program (who fulfil the inclusion criteria mentioned above) are 
automatically included in this study.  
A specially designed questionnaire (the TIPP Initial Assessment Tool: TIAT, available 
upon request) is completed for all patients enrolled in the program by case managers who have 
up to one hundred contacts with patients during the three years of treatment. It allows 
assessment of demographic characteristics, past medical history, exposure to life events as well 
as symptoms and functioning. It is completed on the basis of information gathered from patients 
and their family over the first weeks of treatment and can be updated during follow up if new 
information emerges. Follow-up assessments exploring various aspects of treatment and co-
morbidities as well as evolution of psychopathology and functional level are conducted by a 
psychologist and by case managers at baseline, after 2, 6, 12, 18, 24, 30 and 36 months in 
treatment. Symptoms assessment was conducted by a psychologist who was 100% 
independent of patients’ treatment and had received standardized training prior to the study. 
Inter rater reliability standards for the PANSS (Kay et al. , 1991) have been verified throughout 
the training using video-taped interviews and consensus reference ratings. 
The current paper is based on the prospective follow-up of the first 229 patients who had 
been enrolled in TIPP and where 36 months had elapsed since entry to the program by January 
2014. This study focused on assessments made 2 and 6, 12, 24 and 36 months after entry to 
the program. Eight patients were excluded because they were early drop-outs and for whom 
estimation of DUP was made impossible by the very short time spent in the program.  
 
Measures 
Diagnostic Assessment 
Diagnosis is the result of an expert consensus and is based on the following elements: 
(1) Diagnosis reported by a treating psychiatrist in all medical documents and at the end of any 
hospitalization; (2) Longitudinal assessment by clinical case managers over the 3 years of 
treatment. The consensus diagnosis procedure is carried out by a senior psychiatrist and the 
senior psychologist who is in charge of scale based assessment over the treatment period. 
They both review the entire file once after 18 months and again after 36 months, or at the end of 
treatment. They then conduct a diagnostic process based on DSM-IV criteria (American 
Psychiatric Association, 1994) discussing any unclear issue with the clinical case managers. In 
this paper, only the final diagnosis, defined at the end of TIPP treatment period, was 
considered. 
 
Duration of untreated psychosis (DUP)  
DUP was measured using three progressively more stringent criteria to define treatment 
onset according to Polari et al. (2009): DUP1, DUP2 & DUP3 were obtained on the basis of an 
expert consensus and were considered as the time between the time of onset of psychotic 
symptoms and the time where patient met 3 distinct definitions: (1) initiation of antipsychotic 
medication (DUP1), (2) enrolment into the TIPP programme (DUP2) (3) enrolment into the TIPP 
programme and adherence to adequate medication as defined by current clinical guidelines 
(DUP3). This latter definition was chosen in order to take into account international guidelines 
which suggest that adequate treatment is not limited to adherence to medication and should 
combine it with psychosocial intervention. Treatment adherence was assessed by the case 
managers during the follow-up with a Treatment Adherence Scale (TAS) that ranges from 0 to 
2; 0 being non adherence; 1 partial adherence (from 25% to 75% of the time during the 
evaluation period); and 2 total adherence (from 75% to 100% of the time during the evaluation 
period).  
 
Pre-treatment, baseline and outcome characteristics 
(i) Pre-treatment characteristics: The premorbid functioning was assessed using the 
Premorbid Adjustment Scale (PAS; Cannon-Spoor et al. , 1982). It was delineated into the 
academic and social sub-scores and in childhood and early adolescence sub-scores (MacBeth 
and Gumley, 2008). Past psychiatric diagnoses were assessed according to DSM-IV criteria, 
and past suicide attempts according to ICD-10 classification (Dilling and Dittmann, 1990). Past 
history of trauma was assessed by case managers on the basis of the knowledge of history of 
patients in the frame of a 3 year’s trusting relationship, and based on interviews with relatives 
(Alameda et al. , in press-a, Alameda et al. , in press-b). Socio-economic status (SES) was 
subdivided into high, intermediate and low according to others (Chandola and Jenkinson, 2000). 
Diagnosis of substance abuse or dependence before the disease was rated by case managers 
based on the DSM-IV (American Psychiatric Association, 1994). 
(ii) Patients characteristics at baseline: Patients were rated as “working” at entry 
(baseline) on the basis of the Modified Vocational Status Index (MVSI; Tohen et al. , 2000): i.e., 
paid or unpaid full- or part-time employment, being an active student in school or university, or 
head of household with employed partner (homemaker), or full or part-time volunteer. Patients 
were rated as “living independently” on the basis of the Modified Location Code Index 
Independent living (MLCI; Tohen, Hennen, 2000): i.e., head of household, living alone, with 
partner, or with peers, and living with family with minimal supervision. The level of functioning at 
baseline was estimated by a composite overall score with the Global Assessment of Functioning 
(GAF; American Psychiatric Association, 1994) and with Social and Occupational Functioning 
Assessment Scale (SOFAS; American Psychiatric Association, 1994). A best lifetime score for 
the GAF and SOFAS was also estimated. While the SOFAS only takes the social and 
occupational functioning into account, the GAF also includes the intensity of symptoms. 
Baseline substance use was assessed with the Case Managers Rating Scale (CMRS; Drake et 
al. , 1990) that ranges from 1 to 5, 1 being absence of substance use and 5 very severe 
substance use. Insight into illness was assessed on the basis of one item with anchors ranging 
between absent, partial and complete (Conus et al. , 2007).  
(iii) Outcome measures after 2, 6, 12, 24, and 36 months of follow-up: The functional 
measures with GAF and SOFAS and the percentage of patients with complete adherence 
(according to the TAS) were also assessed at each time point of the follow-up. Additionally the 
following psychopathological measures were assessed at each time point: 1) the level of 
positive and negative symptoms, using the total score of the positive and negative components 
of the Positive and Negative Syndrome Scale (PANSS; Kay et al. , 1987); 2) the level of 
depressive symptoms, using the total score of the Montgomery-Asberg Depression Rating 
Scale (MADRS; Montgomery and Asberg, 1979); 3) the level of manic symptoms, using the total 
score of the Young Mania Rating Scale (YMRS; Young et al. , 1978).  
 
Outcomes definitions at discharge 
Symptomatic remission at discharge was based on the Andreasen Criteria which is the 
simultaneous ratings of mild or less (≤3) on selected PANSS’ items (delusion, unusual thought 
content, hallucinatory behaviour, conceptual disorganization, mannerisms, blunted affect, social 
withdrawal and lack of spontaneity) maintained over 6 months (Andreasen et al. , 2005). 
Functional recovery was operationalized as a final PAS score less than or equal to the 
premorbid rating on four of the five items of the PAS general scale (Strakowski et al. , 1998). 
Ratings on education and abruptness in the change in work were not included in this definition, 
as they could not have changed during the outcome period (Conus, Cotton, 2007).  
 
Statistical analysis 
Considering that many patients became compliant to medication only after some time in 
treatment, DUP3, which includes compliance to medication in its definition, could keep 
increasing over time. Accordingly, DUP3 values were computed at each time-point and were 
used with the outcomes measured of the exact same time. In consequence, the independent 
variable is always calculated in a timely manner with regards to the outcome variable of interest, 
which precisely prevents the assessment of the impact of this independent variable when that 
variable is not yet calculated at the time of the outcome variable. To evaluate to which extent 
each DUP definition could predict the different outcomes, we proceeded in two steps. First we 
used a series of linear regression where each of the three DUP value obtained on the basis of 
the 3 definitions was introduced as the only independent variable in order to determine whether 
each DUP could predict different outcomes. Second, in order to determine the best predictor for 
each outcome, a stepwise multiple regression was estimated with all DUP values as 
independent variables. Stepwise forward likelihood ratio logistic regressions were used for 
analysis involving dichotomous outcomes (remission & recovery). Because DUP values were 
highly skewed, comparisons were performed using Wilcoxon Signed rank tests and DUP values 
were Log10 transformed prior to introduction into the regression and correlations (Gumley et al. , 
2014, Hill et al. , 2012, Hui et al. , 2013, Marshall, Lewis, 2005). Characteristics of patients that 
met the restrictive criteria of adequate medication with  good compliance at the end of the 
follow-up were compared to patients who did not. Differences between these two groups on 
demographic, premorbid, functional and clinical variables were compared with independent t-
tests when the dependent variable was continuous and Chi squared test (or Fisher Exact tests 
when appropriate) when the dependent variable was categorical. Data are presented 
descriptively using mean (M) and standard deviation (SD) or median (Mdn) and interquartile 
range (IQR) for the DUP values. All statistical analyses were performed with IBM SPSS 22. All 
statistical tests were two-tailed and significance was determined at the .05 level.  
 
RESULTS 
Descriptive statistics for the three DUP are presented in Table 1. While DUP1 and DUP2 
values did not vary over the time, DUP3 values could increase significantly during the follow-up 
(Z = -8.823, p <.001) considering the substantial number of patients who became adherent to 
medication only after a few weeks to months in treatment. It is worth noting that 9.1% patients 
never became adherent to medication, and therefore never met the definition of end of DUP3 
(Figure 1). The most restrictive definitions were associated with considerably longer DUP 
values: at discharge, the median DUP3 (405.00 days) was significantly larger than the median 
DUP2 (127.00 days) which was also larger than the median DUP1 (19.00 days) (all p<.001; 
Table 1). Demographic, premorbid, functional and clinical characteristics of the 221 patients are 
presented in Table 2. 
 Prediction of symptomatic and functional outcomes 
A summary of significant predictors of various symptomatic and functional outcomes is 
presented in Table 3. Results of the regression models revealed that except for the 2-month 
assessment (where no DUP definition was able to predict the PANSS positive score) DUP3 was 
systematically the best predictor of positive symptoms across 6 to 36 month with percent of 
explained variance (R2) varying from 4.4% to 10.5%. For negative symptoms, only long term 
outcomes (24 and 36 months) could be predicted by DUP. Again, DUP3 showed to be the best 
predictor and accounted for between 3.9 to 6.0% of variance. Globally, whatever the definition, 
DUP never significantly predicted MADRS score (with the exception of DUP1 at the 12 month 
time-point). Results for the YMRS score were also less consistent than results for the PANSS 
score: YMRS score could only be predicted for the 6 and 12 month time-points by DUP2 and 
DUP3 scores; DUP3 showed to be the best predictor on both occasions (R2 = 3.8% & R2 = 7.7% 
respectively). Overall, DUP3 explained 2.4 times respectively 1.6 times more variance than 
DUP1 and DUP2 with symptomatic outcomes. 
Regarding functional outcome, SOFAS and GAF scores were considered: DUP could 
only predict functional outcome in the long run (12, 24 & 36 months). Five out of 6 times, DUP3 
showed to be the best predictor accounting for between 4.0% to 6.6% of the variance. It should 
be noted that in accordance to the most commonly used DUP criterion (DUP1), association 
between DUP and outcomes could only be described as very weak. Overall, DUP3 explained 
1.6 times more variance than DUP1 and DUP2 with functional outcomes. 
Results of symptomatic remission and functional recovery at discharge are presented in 
Table 4. Once again, the first definition (DUP1) greatly underestimated the relationship between 
DUP and important outcomes at discharge. Symptomatic remission (PANSS Andreasen criteria) 
could be predicted by DUP2 and DUP3. However DUP3 was the best predictor (Odd ratio = 
.375, p = .001, R2 = .183). All three DUP significantly predicted functional recovery (PAS 
Strakowski criteria) but DUP3 provided the best prediction (Odd ratio = .534, p = .003, R2 = 
.098). For functional recovery as operationalized by MLCI and MVSI scales, results were more 
contrasted: DUP1 and DUP2 were not related to functional recovery for both the MLCI and 
MVSI while DUP3 could predict Independent Living (Odd ratio = .584, p = .006, R2 = .063) but 
not Working (Odd ratio = .779, p = .161, R2 = .015). Finally, only DUP3 was related to functional 
recovery using the combined criteria (MLCI and MVSI; Odd ratio = .610, p = .015, R2 = .051). 
Overall, effect sizes for DUP3 were 5.3 times respectively 1.5 times larger than for DUP1 and 
DUP2 with symptomatic outcomes. Taken altogether, these results consistently depict DUP3 as 
a better predictor of important outcomes at discharge.  
 
Characteristics of patients who remained on adherent to treatment and medication 
Results are presented in 2 parts. First, baseline variables that are correlated with DUP3 
are presented. Second, characteristics of patients that met DUP3 criteria by the end of the 
follow-up (N = 201; 90.9%) were compared to patients who did not (N = 20; 9.1%). Longer 
DUP3 were correlated with lower best lifetime GAF scores (r = -.209, p = .002, R2 = .044), lower 
best lifetime SOFAS scores (r = -.195, p = .005, R2 = .038), poorer PAS Academic scores (r = 
.151, p=.044, R2 = .023) and younger age at psychosis onset (r = -.314, p <.001, R2 = .097). 
Patients who never met criteria for DUP3 were more likely to have a lifetime diagnosis of 
cannabis abuse (2(1) = 6.276, p = .012, Odd ratio = 3.48) or cannabis dependence (2(1) = 
8.078, p = .004, Odd ratio = 3.92), had higher cannabis use at baseline (t (219)= 2.199, p = 
.029), were more likely to have committed suicide attempts (2(1) = 4.160, p = .041, Odd ratio = 
2.89) and had lower insight at all assessment points (all p<.05). 
 DISCUSSION 
To the best of our knowledge, this is the first prospective study in EP patients examining the 
impact of DUP on clinical and functional outcomes according to several definitions of treatment 
initiation.  
Firstly, our results clearly show that defining end of DUP either on the basis of the date of 
“initiation of an antipsychotic medication” (DUP1) or on that of “entry to a specialized program” 
(DUP2) erroneously suggest that DUP has come to an end, since at each of these time points, 
an important proportion of patients are not yet engaged in treatment and/or do not take any 
medication. This issue is critical, considering that in the absence of sound evidence that 
treatment delay has an impact on outcome, the validity of the early intervention concepts can 
legitimately be questioned (Barnes et al. , 2000, Ho and Andreasen, 2001). While it seems 
obvious that a prerequisite for the assessment of the impact of delayed initiation of a treatment 
should be that this treatment has actually been initiated, most previous publications have not 
clearly taken this into account and it is likely that the contradictory and inconclusive nature of the 
results gathered so far in this domain may be linked to such a problem of definition.  
This hypothesis seems to receive support from our study. While analyses based on less 
restrictive definitions for treatment onset (DUP1 and DUP2) were in line with previous papers 
and suggested that DUP was only marginally related to both symptomatic and functional 
outcome, the application of a more restrictive definition, based on both engagement in the TIPP 
program and adherence to medication (DUP3), revealed a stronger correlation between DUP 
and most aspects of outcome. Other studies have typically reported small effect sizes by 
traditional standards (Cohen, 1988) with around 5% of explained variance (Harrigan, McGorry, 
2003, Schimmelmann et al. , 2008). In the present study, DUP3 effect sizes for some outcomes 
(PANSS positive score and symptomatic remission) fall in the medium range (Cohen, 1988). 
More research is however needed to confirm these results in larger cohorts and in different 
settings. 
Secondly, our data revealed that DUP, whatever the definition applied, was mainly correlated 
with longer term aspects of outcome (36 months): DUP3 was significantly correlated with most 
aspects of symptomatic and functional outcome at 12, 24 and 36 months, but not at 2 and 6 
months and was a better predictor of symptomatic remission and functional recovery at 
discharge. This is in line with a study from Marshall et al. (2005) who found that correlations 
between DUP and outcome were small or not significant at first presentation but became 
statistically significant for most outcomes by 6- and 12-month follow-up. It is also congruent with 
a retrospective study conducted by Primavera et al. (2012) in a sample of patients with 
schizophrenia, where a shorter DUP was a significant predictor of outcome after 16 to 33 years 
of illness. Such data suggest that delayed treatment has limited impact on symptom intensity, 
but that it significantly influences potential for response to treatment and therefore hampers 
recovery. 
Thirdly, we found that close to 10% of patients did never fulfil criteria for DUP3, and therefore 
were never exposed to adequate treatment of the 36 months of care in our specialized program. 
While this prevalence is about half of what Lambert et al. (2010) have reported in a 
retrospective study on a large sample of EP patients, the characteristics of these “medication 
refusers” are similar in both studies, and suggest that patients with poor premorbid adjustment, 
low level of insight and active substance abuse are at high risk not to be exposed to adequate 
treatment, and hence prolonged DUP. Specific strategies to facilitate engagement of such 
patients are therefore needed.  
Some limitations of our study should be mentioned. First, even if a consensus exists regarding 
the definition and tools that can be applied to define psychosis onset, a precise dating of this 
event remains difficult. In the current study, a particular effort was made to update its evaluation 
throughout the treatment period whenever new information allowed a more precise estimation of 
this date. Second, because a small number of patients who were poorly engaged in treatment 
were excluded from the study due to lack of information, it could be argued that results of the 
current study are biased towards more compliant patients. However, the study being based on 
the clinical data gathered in the context of the prospective follow-up of all patients treated at our 
program who could be at least minimally assessed, the TIPP cohort is likely to be highly 
representative of EP patients in our catchment area. Thirdly, the definition of DUP3 is based on 
engagement in the TIPP program and adherence to medication; reaching these conditions may 
however coincide with other modifications such as interruption of substance abuse or 
acquisition of better coping strategies to face the illness, factors which may also play important 
roles regarding better outcome. 
 
Conclusion 
Despite these limitations, our study showed that when defined on the basis of engagement in a 
specialized treatment and adherence to medication, DUP is a significant predictor of outcome. 
While other studies based on a similar definition are needed in order to confirm our findings, 
these results suggest that early intervention and identification strategies are justified. They also 
suggest that additional effort should be put in the development of strategies facilitating 
engagement and adherence to treatment in patients with poor premorbid functioning, low level 
of insight and persistent substance abuse disorder, considering they may fail to be exposed to 
all the facets of treatment despite having been enrolled in a specialized program.   
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Table 1. Duration of untreated psychosis (DUP). 
DUP in days, Median (IQR) computed at 
 baseline 
computed at  
discharge 
DUP1 19.00 (153.50) 19.00 (153.50) 
DUP2 127.00 (652.50) 127.00 (652.50) 
DUP3 127.00 (652.50) 405.00 (1035.00) 
Comparison of DUP valuesa  statistic p-value 
DUP3 computed at baseline vs 
DUP3 computed at discharge 
Z = -8.823 <.001 
   
DUP computed at discharge   
   DUP1 vs DUP2 Z = -8.723 <.001 
   DUP1 vs DUP3 Z = -12.092 <.001 
   DUP2 vs DUP3 Z = -8.823 <.001 
Note. IQR = Interquartile range. a = Wilcoxon Signed rank test.  
  
Table 2. Patients demographic, premorbid, functional and clinical variables characteristics. 
 Total patients 
N = 221 
Age in y, Mean (SD) 24.17 (4.92) 
 
Sex, male, % (N)  
 
69.2 (153) 
 
SES, % (N) 
Low 
Intermediate 
High  
 
 
16.7 (37) 
47.1 (104) 
36.2 (80) 
 
Trauma (non exposed), % (N) 
 
63.3 (140) 
 
Age at onset of psychosis, Mean (SD) 
 
23.00 (5.31) 
 
Diagnostic, % (N) 
Schizophrenia 
Schizophreniform/brief psychotic episode 
Schizoaffectif disorder 
Major depression with psychotic features 
Bipolar disorder 
Others  
 
 
62.0 (137) 
11.3 (25) 
10.0 (22) 
3.6 (8) 
5.9 (13) 
7.2 (16) 
 
PAS scores, Mean (SD) 
Childhood 
Early adolescence 
Social 
Academic 
Total 
 
 
0.31 (0.19) 
0.33 (0.18) 
0.29 (0.21) 
0.36 (0.20) 
0.32 (0.17) 
 
PANSS positive, Mean (SD) 
 
13.33 (4.88) 
 
PANSS negative, Mean (SD) 
 
15.24 (5.91) 
 
MADRS, Mean (SD) 
 
14.76 (9.79) 
 
YMRS, Mean (SD) 
 
6.10 (5.70) 
 
GAF Baseline, Mean (SD) 
 
35.07 (15.67) 
 
GAF Best Lifetime, Mean (SD) 
74.21 (13.27) 
 
SOFAS Baseline, Mean (SD) 
 
38.13 (16.10) 
 
SOFAS Best Lifetime, Mean (SD) 
 
74.88 (12.77) 
PANSS = Positive and Negative Syndrome Scale. MADRS = Montgomery Asberg Depression 
Rating Scale. YMRS = Young Mania Rating Scale. SOFAS = Social and Occupational 
Assessment of functioning Scale. GAF = Global Assessment of Functioning Scale. 
 
Table 3. Summary of predictors of symptomatology and functioning during the follow-up. 
 2 months  6 months  12 months  24 months  36 months 
 DUP1 DUP2 DUP3  DUP1 DUP2 DUP3  DUP1 DUP2 DUP3  DUP1 DUP2 DUP3  DUP1 DUP2 DUP3 
PANSS 
positive 
     x B   x B  x x B  x x B 
PANSS 
negative 
            x  B    B 
MADRS         B           
YMRS      x B   x B         
SOFAS          x B    B  x  B 
GAF   B       x B    B  B  x 
Effect 
sizes R2 
                   
                    
PANSS 
positive 
.004 .001 .009  .007 .033 .044  .007 .052 .090  .033 .069 .075  .079 .074 .105 
PANSS 
negative 
.003 .000 .002  .002 .004 .000  .000 .004 .001  .033 .030 .039  .021 .028 .060 
MADRS .038 .008 .004  .001 .000 .001  .050 .037 .025  .005 .010 .006  .025 .000 .002 
YMRS .001 .000 .003  .013 .033 .038  .002 .025 .077  .018 .032 .028  .032 .020 .015 
SOFAS .004 .005 .012  .000 .000 .001  .014 .028 .054  .007 .005 .034  .027 .014 .047 
GAF .006 .009 .022  .002 .005 .013  .018 .040 .066  .010 .008 .036  .042 .016 .040 
Note. x = significant predictor (p<.05). B = best significant predictor. PANSS = Positive and Negative Syndrome Scale. MADRS = 
Montgomery Asberg Depression Rating Scale. YMRS = Young Mania Rating Scale. SOFAS = Social and Occupational Assessment 
of functioning Scale. GAF = Global Assessment of Functioning Scale. Effect sizes are presented in bold when the predictor is 
statistically significant. 
 
 
 
 
Table 4. Summary of predictors of symptomatic remission and functional recovery at discharge. 
 36 months 
 DUP1 DUP2 DUP3 
Symptomatic remission (PANSS)a  x B 
Functional recovery (PAS)b x x B 
Functional recovery – Living Independently (MLCI)   B 
Functional recovery - Working (MVSI)    
Functional recovery – Combined (MLCI + MVSI)   B 
Effect sizes Odds Ratios / Nagelkerke R2    
    
Symptomatic remission (PANSS)a .859 / .010 .483 / .121 .375 / .183 
Functional recovery (PAS)b .731 / .044 .543 / .092 .534 / .098 
Functional recovery – Living Independently (MLCI) .853 / .009 .732 / .022 .584 / .063 
Functional recovery - Working (MVSI) .871 / .009 .771 / .017 .779 / .015 
Functional recovery – Combined (MLCI + MVSI) .879 / .006 .756 / .016 .610 / .051 
Note. x = significant predictor (p<.05). B = best significant predictor. a = based on the 
Andreasen criteria (PANSS). b = based on Strakowski criteria. PANSS = Positive and Negative 
Syndrom Scale. PAS = Premorbid Adjustment Scale. MLCI = Modified Location Code Index 
Independent living. MVSI = Modified Vocational Status Index. Effect sizes are presented in bold 
when the predictor is statistically significant. 
 
 
  
Figure 1. Percentage of patients having received first antipsychotic medication and effective 
treatment (adequate medication with a good compliance) across 36 months. 
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